373 related articles for article (PubMed ID: 19642570)
1. [Estimation of the clinical and pharmacoeconomic efficiency of treatment in patients with community-acquired pneumonia with third-generation cephalosporins].
Starodubtseva OI; Vakhrushev IaM
Probl Tuberk Bolezn Legk; 2009; (6):28-9. PubMed ID: 19642570
[TBL] [Abstract][Full Text] [Related]
2. [Comparative assessment of efficacy of the 3d generation cephalosporins, ceftriabol, and claforan, in patients with community-acquired pneumonia].
Vakhrushev IaM; Starodubtseva OI
Klin Med (Mosk); 2009; 87(7):53-5. PubMed ID: 19705794
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacoeconomic estimation of cost of community acquired pneumonia therapy].
Kulidzhanov AIu; Sirotko II; Koriakin PM; Korchazhkin VS
Voen Med Zh; 2001 Jan; 322(1):50-2. PubMed ID: 11219929
[No Abstract] [Full Text] [Related]
4. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
5. [The clinical and economic aspects of treating community-acquired pneumonias].
Tiurin VP; Dmitriev IuK; Duganov VK; Bogdanov MB
Voen Med Zh; 2000 Apr; 321(4):28-31. PubMed ID: 10860468
[No Abstract] [Full Text] [Related]
6. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
7. [Clinical efficacy of probiotics in complex treatment of called-up servicemen with community-acquired pneumonia].
Rakov AL; Grinevich VB; Kriukov AE; Bogdanov IV; Rysev AV; Zakharchenko MM; Dobrenko VA; Gubonina IV
Voen Med Zh; 2006 Apr; 327(4):15-22. PubMed ID: 16784101
[No Abstract] [Full Text] [Related]
8. Antibiotic treatment of community acquired pneumonia varies widely across Germany.
Kohlhammer Y; Raspe H; Marre R; Suttorp N; Welte T; Schäfer T;
J Infect; 2007 May; 54(5):446-53. PubMed ID: 17007933
[TBL] [Abstract][Full Text] [Related]
9. Clinical and economic outcomes in the treatment of lower respiratory tract infections.
Brixner DI
Am J Manag Care; 2004 Oct; 10(12 Suppl):S400-7. PubMed ID: 15603249
[No Abstract] [Full Text] [Related]
10. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
11. Community-acquired pneumonia: treatment at home or in the hospital?
Aujesky D; Fine MJ
Am J Med; 2008 Dec; 121(12):1038-40. PubMed ID: 19028194
[No Abstract] [Full Text] [Related]
12. Initial antibiotic selection and patient outcomes: observations from the National Pneumonia Project.
Bratzler DW; Ma A; Nsa W
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S193-201. PubMed ID: 18986289
[TBL] [Abstract][Full Text] [Related]
13. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
Rahav G; Fidel J; Gibor Y; Shapiro M
Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
[TBL] [Abstract][Full Text] [Related]
15. [Multicenter study of the variability and adequacy of antimicrobial therapy for community-acquired pneumonia in adults].
Artero A; Eiros JM; Ochoa C; Inglada L; Guerra L; Armadans L; Vallano A; Vidal JB; Martínez A; Lázaro A; Cerdá T; Ruiz A
Rev Esp Quimioter; 1999 Dec; 12(4):352-8. PubMed ID: 10855015
[TBL] [Abstract][Full Text] [Related]
16. In-hospital management of adults who have community-acquired pneumonia.
Ortqvist A
Semin Respir Infect; 1999 Jun; 14(2):135-50. PubMed ID: 10391408
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
18. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
[TBL] [Abstract][Full Text] [Related]
19. What are the properties that make an antibiotic acceptable for therapy of community-acquired pneumonia?
Drusano GL
J Antimicrob Chemother; 2011 Apr; 66 Suppl 3():iii61-7. PubMed ID: 21482571
[TBL] [Abstract][Full Text] [Related]
20. Clinical trial design for mild-to-moderate community-acquired pneumonia--an industry perspective.
Echols RM; Tillotson GS; Song JX; Tosiello RL
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S166-75. PubMed ID: 18986284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]